Is VOR or VRTX more undervalued in 2026?

CirclFi compares Vor Biopharma Inc. (VOR) and Vertex Pharmaceuticals Incorpor (VRTX) using 13 institutional-grade valuation models. VOR has a Quality of Company score of 3.5/10 while VRTX scores 10.0/10.

Which is a better buy — VOR or VRTX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do VOR and VRTX valuations compare?

VOR at $15.01 and VRTX at $447.97 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

VOR vs VRTX Valuation Comparison 2026 — Intrinsic Value Analysis

VOR

Biotechnology

Vor Biopharma Inc.

Quality

3.5

out of 10

Value Trap

LOW

Price

$15.01

Last close

Models

7/13

Active

VRTX

Biotechnology

Vertex Pharmaceuticals Incorpor

Quality

10.0

out of 10

Value Trap

SAFE

Price

$447.97

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	VOR Fair Value	VOR Upside	VRTX Fair Value	VRTX Upside
Bayesian DCF	Intrinsic	$5.72	-61.9%	$269.49	-39.8%
Earnings Power Value	Intrinsic	—	—	$154.03	-65.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$25.80	+71.9%	$441.27	-1.5%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for VOR vs VRTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VOR vs VRTX — Which Stock Is More Undervalued?

VRTX scores higher with a 10.0/10 quality rating vs VOR's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Vor Biopharma Inc. (VOR) and Vertex Pharmaceuticals Incorpor (VRTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VOR currently trades at $15.01 with a QOC of 3.5/10, while VRTX trades at $447.97 with a QOC of 10.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).